Table 1.
Overall response rate of ICIs for patients with stage 4 neuronal subtype UC including SCCB
| Author | Patients | Treatment | Number of patients | Response | |
|---|---|---|---|---|---|
| ORR (%) | Best response | ||||
| Kim et al. 12 | Patients with platinum‐refactory or cisplatin‐ineligible neuronal subtype UC | Atezolizumab | 11 | 72% | Complete response 2 |
| Partial response 6 | |||||
| Not able to assess 3 | |||||
| Miller et al. 13 | Patients who received anti‐PD‐1 or PD‐L1 for UC with neuroendcrine feature | Atezolizumab | 6 | 25% | complete response + partial response 2 |
| Durvalumab | 1 | No response 6 | |||
| Nivolumab | 1 | Not able to assess 1 | |||
| Pembrolizumab | 1 | ||||